欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Afatinib_850140-72-6_产品详情
850140-72-6
  • names:

    Afatinib

  • CAS号:

    850140-72-6

    MDL Number:
  • MF(分子式): C24H25ClFN5O3 MW(分子量): 485.94
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Afatinib
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM001814-50mg 50mg 99.99% ¥ 2565.00 ¥ 2565.00 2-3天
- +
¥ 0.00
YZM001814-10mg 10mg 99.99% ¥ 910.00 ¥ 910.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 850140-72-6
Inchi
InchiKey
分子式 Formula C24H25ClFN5O3
分子量 Molecular Weight 485.94
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 100 mg/mL(205.79 mM)H2O< 0.1 mg/mL(insoluble)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Afatinib(CAS:850140-72-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Afatinib (BIBW 2992) 为不可逆的EGFR家族抑制剂,抑制EGFRwt,EGFRL858R,EGFRL858R/T790M和 HER2的IC50分别为0.5 nM,0.4 nM,10 nM 和 14 nM
IntroductionAfatinib (BIBW 2992) is an irreversibleEGFRfamily inhibitor withIC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790Mand HER2, respectively.
Application1
Application2
Application3
Afatinib (BIBW 2992) 为不可逆的EGFR家族抑制剂,抑制EGFRwt,EGFRL858R,EGFRL858R/T790M和 HER2的IC50分别为0.5 nM,0.4 nM,10 nM 和 14 nM。Afatinib (BIBW 2992) is an irreversibleEGFRfamily inhibitor withIC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790Mand HER2, respectively.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-11.
【2】.Wong CH, et al. Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). Am J Cancer Res. 2015 Nov 15;5(12):3588-99.
【3】.Wang XK, et al. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 2014 Dec 15;5(23):11971-85.
【4】.Yoshioka T, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018 Apr;109(4):1166-1176.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents